Serif Biomedicines

Stub active Updated Apr 25, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Location Cambridge, MA
Founded 2021
Latest Stage Initial Funding
Total Raised $50M
Website https://serifbio.com
Sector
biotech genetic-medicine dna-medicine life-sciences

About

Serif Biomedicines is a Cambridge-based biotech founded in 2021 within Flagship Labs that is developing modified DNA as a new class of genetic medicine, integrating nucleic acid chemistry, synthetic biology, delivery science, and AI to create programmable, scalable, durable, and redosable DNA-based therapeutics 12. Modified DNA aims to combine the best features of mRNA and gene therapy while mitigating their limitations 1.

Funding History

Date Round Amount Lead Co-investors
2026-04-21 Initial Funding $50M Flagship Pioneering 12

What Investors Say

No independently sourced investor quotes found.

What Founders Say

No independently sourced founder quotes found.

Sources

  1. Flagship Pioneering, “Flagship Pioneering Launches Serif Biomedicines to Establish Modified DNA as a New Biotechnology,” April 21, 2026. https://www.flagshippioneering.com/news/press-release/flagship-pioneering-launches-serif-biomedicines-to-establish-modified-dna-as-a-new-biotechnology↩↩↩

  2. BioPharma Dive, “Serif, Flagship’s latest biotech, aims to make a new kind of genetic medicine,” April 21, 2026. https://www.biopharmadive.com/news/serif-flagship-biotech-startup-modified-dna-mrna/817719/↩↩